AssayIndex

MKM-2504-F3495

Retatrutide · 30 mg declared · Xi'an Mokemei Biotechnology Co., Ltd. · manufactured 24 Apr 2025

CHARACTERISED
Lot code
MKM-2504-F3495
Supplier
MKM — Xi'an Mokemei Biotechnology Co., Ltd.
Compound
Retatrutide
Compound class
Incretin analogues and co-agonists
Declared label claim
30mg
Manufacture date
24 Apr 2025
Index quarter
2025-Q2
Independent assays
3
Laboratories involved
PeptideMeter, Janoshik
Provenance mix
Supplier-supplied ×3
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 3
Median purity 98.36% n=3
Spread (max − min) 0.27pp n=3
Standard deviation 0.146pp n=3
95.196.096.897.798.699.4100.3This lot (MKM-2504-F3495)This lot (MKM-2504-F3495): Q1 98.34, median 98.36, Q3 98.47, n=3n=3All RetatrutideAll Retatrutide: Q1 97.75, median 98.41, Q3 98.87, n=496outlier 95.45outlier 95.54outlier 95.67outlier 95.97n=496 Purity (% area)
Figure 1. This lot's independent purity results against the whole Retatrutide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 96.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 3

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-020372MKM-2504-F3495PeptideMeter2025-Q298.326.90Supplier-supplied1MARGINAL
AX-2025-020373MKM-2504-F3495Janoshik2025-Q298.597.12Supplier-supplied1MARGINAL
AX-2025-020374MKM-2504-F3495Janoshik2025-Q298.367.1990.6Supplier-supplied1MARGINAL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
PeptideMeter198.3298.3228min-0.0598.37
Janoshik298.59, 98.3698.4730min+0.0098.47

This lot contributes 1 paired comparison to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)98.6898.32divergence +0.32 pp vs batch median
Total impurities (% area)1.321.68
Largest single impurity (% area)not stated0.90
Water (%)5.16.90
Counter-ion (%)not stated5.88
Peptide content (%w/w)90.1not determined
Endotoxin (EU/mg)not statednot determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
des-Aib20 analogue3 / 30.880.04–0.90
[D-Aib2]-diastereomer3 / 30.400.39–0.76
oxidised Trp (+16 Da)3 / 30.200.20–0.22
C18 diacid regioisomer3 / 30.040.02–0.05
truncated (5-39)3 / 30.040.04–0.05
retatrutide dimer2 / 30.090.09–0.09
aspartimide (−18 Da)1 / 30.32
Section 7

What this rollup does not establish